

**Human Apolipoprotein C-II (Apo C-II) protein**

□ Cat. # APOC25-N-50 Purified Human Apo C-II protein, VLDL

**SIZE:** 50 ug

Apolipoproteins are proteins that bind to fats (lipids). They form lipoproteins, which transport dietary fats through the bloodstream. Dietary fats are digested in the intestine and carried to the liver. Fats are also synthesized in the liver itself. Fats are stored in fat cells (adipocytes). Fats are metabolized as needed for energy in the skeletal muscle, heart, and other organs and are secreted in breast milk. Apolipoproteins also serve as enzyme co-factors, receptor ligands, and lipid transfer carriers that regulate the metabolism of lipoproteins and their uptake in tissues.

Apolipoprotein C-II is a protein that in humans is encoded by the APOC2 gene. The protein encoded by this gene is secreted in plasma where it is a component of very low density lipoprotein. This protein activates the enzyme lipoprotein lipase, which hydrolyzes triglycerides and thus provides free fatty acids for cells. Mutations in this gene cause hyperlipoproteinemia type IB, characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis. The concentration of Apo CII in normal plasma is 3-8 mg per 100 ml.

**Source of Antigen, Antibodies, and positive controls**

**Cat# APOC25-N-50**

Human Apo C-II was purified from plasma (>95%, 8.8 Kda). It is supplied lyophilized in a buffer (10 mM NaHCO<sub>3</sub>, pH 7.4). All human derived material has been tested negative for HIV, HCV, and HbSAg. Nevertheless, all precautions should be taken and samples be treated as potentially hazardous. Store powder at -20oC. Reconstitute powder at 100 ug/ml or higher in PBS or other buffers. Store at -2o0C in suitable aliquots. Stable for up to 6 months.

**Recommended Usage**

**Western Blotting use at 100-500 ng per lane and detect with appropriate antibodies (#APOC22-A).** Human ApoC-II s approx. ~8.8 KDa (1).

**ELISA** (1:10K-1:100K; using 50-100 ng of control peptide/well).

**General References:** Jackson RI (1977) PNAS 74, 1942-1945; Hegley RA (1992) Dis. Markers 9, 73-80; Wei CF (1986) JBC 260, 15211-1521; Baggio G (1986) J. Clin. Invest. 77, 520-527.

\*This product is for In vitro research use only.

**Related material available from ADI**

Catalog#	ProdDescription
APOC11-A	Anti-Human Apolipoprotein C-I IgG, aff pure
APOC11-C	Human Apolipoprotein C-I protein control for WB
APOC15-N-100	correct cat# is APOC11-C; Human Apolipoprotein C-I protein control for WB
APOC15-N-100	Apolipoprotein C-I, Human Plasma, VLDL
APOC21-S	Anti-Human Plasma Apolipoprotein C-II antiserum
APOC22-A	Anti-Human Apolipoprotein C-II IgG, aff pure
APOC22-C	Human Apolipoprotein C-II protein control for WB
APOC25-N-50	Apolipoprotein C-II, Human Plasma, VLDL
APOC32-A	Anti-Human Apolipoprotein C-III IgG, aff pure
APOC32-C	Human Apolipoprotein C-III protein control for WB
APOC35-N-50	Apolipoprotein C-III, Human Plasma, VLDL
Anti-ApoA, ApoB, ApoC, ApoE -Beta amyloid 1-40, 1-42, APP, Parkin, Synucleins ( $\alpha$ , $\beta$ , $\gamma$ ), Presenilins 1, 2, ERAB	
APOC25-N-50	130214A